Early Access — free while we kick the tires
EdgarHawk

Luput Cristian

Director

Director
3 filings analyzed · 1 company · Latest 2025-12-01

Companies

Company Buys Sells Direction
MAIA Biotechnology, Inc. MAIA 4 0 Net buying

Activity

December 2025
medium
Buy
38,145 shares
$41,846
Significance 4/10

Director Luput Cristian buys 38,145 shares at avg $1.10; cluster pattern with 2 other insiders buying within 14 days

Luput Cristian (Director) executed two separate purchases totaling 38,145 shares for $41,845.86 at a blended average price of $1.10 on 2025-11-26 and 2025-11-28, increasing his holdings by 9.5% to 437,628 shares. A cluster pattern is present with 2 other insiders also buying within the past 14 days. However, his same-ticker history at MAIA shows mixed outcomes: of 5 prior trades, only 1 of 4 prior buys achieved positive 90-day returns (well-timed was the 2024-03-14 purchase at +218.0%), while three prior buys resulted in losses ranging from -12.0% to -40.6% at the 90-day mark. The company is unprofitable with net income of $-8,903,189.00 over its most recent full fiscal year, and the stock is -51.6% from its 52-week high, trading at $1.20 against a 52-week range of $0.87–$2.48. The concurrent buying by multiple insiders may indicate shared assessment of current valuation, but the director's own track record at this ticker shows a 25% success rate on prior buys.

November 2025
medium
Buy
10,000 shares
$9,785
Significance 4/10

Director Cristian Luput bought 10,000 MAIA shares at $0.98; stock now $1.18. Cluster pattern: 2 other insiders also bought within 14 days. Stock down 52.4% from 52-week high.

Director Cristian Luput purchased 10,000 shares at $0.98 on 2025-11-25, increasing his holdings to 399.5K shares (+2.6%). The purchase occurs as MAIA stock trades 52.4% below its 52-week high and down 23.4% over the prior 90 days. A cluster pattern is present: 2 other insiders also bought within the past 14 days, suggesting coordinated accumulation activity. However, Luput's historical track record at MAIA shows mixed results—his prior same-ticker buys produced only 1 well-timed outcome at the 90-day mark (33% timing accuracy), with the most recent measurable trade (2024-11-01) posting a 90-day loss of -25.9%. The company posted a net loss of $-8.9M against a market cap of $43.7M, indicating unprofitability in the most recent full fiscal year.

November 2024
medium
Buy
22,133 shares
$55,554
Significance 4/10

MAIA Director Luput Cristian bought 22.1K shares at $2.51; stock down 43.5% from 52-week high; unprofitable company; cluster buy pattern with 3 insiders in 14 days.

Luput Cristian, a Director of MAIA Biotechnology, purchased 22,133 shares at $2.51 on 2024-11-01, increasing his holdings by +6.0% to 389,483 shares. The purchase occurs as the stock trades 43.5% below its 52-week high of $5.10, and follows a 13.8% gain over the prior 30 days. However, his same-ticker history at MAIA shows a poor track record: of 5 prior purchases at this company, only 1 was well-timed at the 90-day mark, with four consecutive buys in April–May 2023 each yielding 90-day losses ranging from -20.9% to -40.6%. The company remains unprofitable with a net loss of $8,879,276.00 and a market cap of $68,852,770.56, suggesting significant structural challenges. A cluster pattern—3 other insiders also bought within the past 14 days—indicates coordinated activity, though the insider's own history of poor timing outcomes at this ticker raises questions about the decision-making context for this filing's transaction.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access